Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers
© 2022. The Author(s)..
The utility of cancer whole genome and transcriptome sequencing (cWGTS) in oncology is increasingly recognized. However, implementation of cWGTS is challenged by the need to deliver results within clinically relevant timeframes, concerns about assay sensitivity, reporting and prioritization of findings. In a prospective research study we develop a workflow that reports comprehensive cWGTS results in 9 days. Comparison of cWGTS to diagnostic panel assays demonstrates the potential of cWGTS to capture all clinically reported mutations with comparable sensitivity in a single workflow. Benchmarking identifies a minimum of 80× as optimal depth for clinical WGS sequencing. Integration of germline, somatic DNA and RNA-seq data enable data-driven variant prioritization and reporting, with oncogenic findings reported in 54% more patients than standard of care. These results establish key technical considerations for the implementation of cWGTS as an integrated test in clinical oncology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Nature communications - 13(2022), 1 vom: 18. Mai, Seite 2485 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shukla, N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.05.2022 Date Revised 16.07.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-022-30233-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34107814X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34107814X | ||
| 003 | DE-627 | ||
| 005 | 20231226010938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-022-30233-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM34107814X | ||
| 035 | |a (NLM)35585047 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shukla, N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a The utility of cancer whole genome and transcriptome sequencing (cWGTS) in oncology is increasingly recognized. However, implementation of cWGTS is challenged by the need to deliver results within clinically relevant timeframes, concerns about assay sensitivity, reporting and prioritization of findings. In a prospective research study we develop a workflow that reports comprehensive cWGTS results in 9 days. Comparison of cWGTS to diagnostic panel assays demonstrates the potential of cWGTS to capture all clinically reported mutations with comparable sensitivity in a single workflow. Benchmarking identifies a minimum of 80× as optimal depth for clinical WGS sequencing. Integration of germline, somatic DNA and RNA-seq data enable data-driven variant prioritization and reporting, with oncogenic findings reported in 54% more patients than standard of care. These results establish key technical considerations for the implementation of cWGTS as an integrated test in clinical oncology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Levine, M F |e verfasserin |4 aut | |
| 700 | 1 | |a Gundem, G |e verfasserin |4 aut | |
| 700 | 1 | |a Domenico, D |e verfasserin |4 aut | |
| 700 | 1 | |a Spitzer, B |e verfasserin |4 aut | |
| 700 | 1 | |a Bouvier, N |e verfasserin |4 aut | |
| 700 | 1 | |a Arango-Ossa, J E |e verfasserin |4 aut | |
| 700 | 1 | |a Glodzik, D |e verfasserin |4 aut | |
| 700 | 1 | |a Medina-Martínez, J S |e verfasserin |4 aut | |
| 700 | 1 | |a Bhanot, U |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez-Abril, J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Fiala, E |e verfasserin |4 aut | |
| 700 | 1 | |a Stockfisch, E |e verfasserin |4 aut | |
| 700 | 1 | |a Li, S |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Sanchez, M I |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donohue, T |e verfasserin |4 aut | |
| 700 | 1 | |a Cobbs, C |e verfasserin |4 aut | |
| 700 | 1 | |a Roehrl, M H A |e verfasserin |4 aut | |
| 700 | 1 | |a Benhamida, J |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias Cardenas, F |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz, M |e verfasserin |4 aut | |
| 700 | 1 | |a Kinnaman, M |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, S |e verfasserin |4 aut | |
| 700 | 1 | |a Ladanyi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Modak, S |e verfasserin |4 aut | |
| 700 | 1 | |a Farouk-Sait, S |e verfasserin |4 aut | |
| 700 | 1 | |a Slotkin, E |e verfasserin |4 aut | |
| 700 | 1 | |a Karajannis, M A |e verfasserin |4 aut | |
| 700 | 1 | |a Dela Cruz, F |e verfasserin |4 aut | |
| 700 | 1 | |a Glade Bender, J |e verfasserin |4 aut | |
| 700 | 1 | |a Zehir, A |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, A |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, M F |e verfasserin |4 aut | |
| 700 | 1 | |a Kung, A L |e verfasserin |4 aut | |
| 700 | 1 | |a Papaemmanuil, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 13(2022), 1 vom: 18. Mai, Seite 2485 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:18 |g month:05 |g pages:2485 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-022-30233-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 1 |b 18 |c 05 |h 2485 | ||